Epstein-Barr virus (EBV) is associated with several tumors, and has substantial relevance for public health. Therapeutics innovation for EBV-related disorders is much needed. In this context, miRNAs are noncoding RNA molecules that play vital roles in EBV infection. miRNA-Seq and RNA-Seq data for EBV-associated clinical samples and cell lines have been generated, but their detailed integrative analyses, and exploitation for drug repurposing against EBV are lacking. Hence, we identified and analyzed the differentially expressed miRNAs (DEmiRs) in EBV-infected cell lines (28) and infected (28) and uninfected human tissue (20) samples using an in-house pipeline. We found significantly enriched host miRNAs like hsa-mir-3651, hsa-mir-1248, and hsa-mir-29c-3p in EBV-infected samples from EBV-associated nasopharyngeal carcinoma and Hodgkin's lymphoma, among others. Furthermore, we also identified significantly enriched novel miRNAs such as hsa-mir-29c-3p, hsa-mir-3651, and hsa-mir-98-3p, which were not previously reported in EBV-related tumors. Differentially expressed mRNAs (DEMs) were identified in EBV-infected cell lines (21) and uninfected human tissue (14) samples. We predicted and selected 1572 DEMs (upregulated) that are targeted by 547 DEmiRs (downregulated). These were further classified into essential (870) and nonessential (702) genes. Moreover, a miRNA-mRNA network was developed for the hub miRNAs. Importantly, we used the DEMs during EBV latent infection types I, II, and III to identify the candidate drugs for repurposing: Glyburide, Levodopa, Nateglinide, and Stiripentol, among others. To the best of our knowledge, this is the first integrative analyses that identified DEmiRs and DEMs as potential therapeutic targets and predicted drugs as potential candidates for repurposing against EBV-related tumors.
Get full access to this article
View all access options for this article.
References
1.
AffresH, SenatM-V, LetourneauA, et al.Glyburide therapy for gestational diabetes: Glycaemic control, maternal hypoglycaemia, and treatment failure. Diabetes Metab, 2021; 47(4):101210; doi: 10.1016/j.diabet.2020.11.002
2.
AmbrosioMR, MundoL, GazaneoS, et al.MicroRNAs sequencing unveils distinct molecular subgroups of plasmablastic lymphoma. Oncotarget, 2017; 8(64):107356–107373; doi: 10.18632/oncotarget.22219
3.
AndersS, PylPT, HuberW. HTSeq—a python framework to work with high-throughput sequencing data. Bioinformatics, 2015; 31(2):166–169; doi: 10.1093/bioinformatics/btu638
AozasaK, TakakuwaT, NakatsukaS. Pyothorax-associated lymphoma: A lymphoma developing in chronic inflammation. Adv Anat Pathol, 2005; 12(6):324–331; doi: 10.1097/01.pap.0000194627.50878.02
6.
AranciaG, RagonaG, RocchiG, et al.Epstein-Barr virus-related ultrastructural modifications of plasma membrane during B-cell transformation. Int J Cancer, 1986; 38(4):549–552; doi: 10.1002/ijc.2910380415
7.
AyoubianH, LudwigN, FehlmannT, et al.Epstein-Barr virus infection of cell lines derived from diffuse large B-cell lymphomas alters microRNA loading of the Ago2 complex. J Virol, 2019; 93(3):e01297-18; doi: 10.1128/JVI.01297-18
8.
BarthaI, di IulioJ, VenterJC, et al.Human gene essentiality. Nat Rev Genet, 2018; 19(1):51–62; doi: 10.1038/nrg.2017.75
9.
BircsakKM, GuptaV, YuenPYS, et al.Genetic and dietary regulation of glyburide efflux by the human placental breast cancer resistance protein transporter. J Pharmacol Exp Ther, 2016; 357(1):103–113; doi: 10.1124/jpet.115.230185
10.
BolgerAM, LohseM, UsadelB. Trimmomatic: A flexible trimmer for illumina sequence data. Bioinformatics, 2014; 30(15):2114–2120; doi: 10.1093/bioinformatics/btu170
BuckML, GoodkinHP. Stiripentol: A novel antiseizure medication for the management of dravet syndrome. Ann Pharmacother, 2019; 53(11):1136–1144; doi: 10.1177/1060028019856008
13.
BurkeAP, YenTS, ShekitkaKM, et al. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol, 1990; 3(3):377–380.
14.
BussonP, ZhangQ, GuillonJM, et al.Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells. Int J Cancer, 1992; 50(6):863–867; doi: 10.1002/ijc.2910500605
15.
CastilloJJ, BeltranBE, MirandaRN, et al.Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: What we know so far. Oncologist, 2011; 16(1):87–96; doi: 10.1634/theoncologist.2010-0213
16.
ChenQ, LiuS, ZhangK, et al.Hsa-MiR-372-5p regulates the NIMA related kinase 7 and IL-1β release in NK/T-cell lymphoma. Leuk Lymphoma, 2021; 62(11):2648–2656; doi: 10.1080/10428194.2021.1933472
17.
ChenY, WangX. MiRDB: An online database for prediction of functional microRNA targets. Nucleic Acids Res, 2020; 48(D1):D127–D131; doi: 10.1093/nar/gkz757
18.
ChinC-H, ChenS-H, WuH-H, et al.CytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst Biol, 2014; 8(Suppl 4):S11; doi: 10.1186/1752-0509-8-S4-S11
19.
CiccocioppoR, MengoliC, BettiE, et al.Human cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis. Clin Exp Med, 2021; 21(3):379–388; doi: 10.1007/s10238-021-00702-2
20.
CosmopoulosK, PegtelM, HawkinsJ, et al.Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol, 2009; 83(5):2357–2367; doi: 10.1128/JVI.02104-08
21.
DargartJL, FishK, GordonLI, et al.Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antiviral Res, 2012; 95(1):49–56; doi: 10.1016/j.antiviral.2012.05.003
22.
DengL, WangX, JiangL, et al.Modulation of MiR-185-5p Expression by EBV-MiR-BART6 contributes to developmental differences in ABCG4 gene expression in human megakaryocytes. Int J Biochem Cell Biol, 2016; 81(Pt A):105–111; doi: 10.1016/j.biocel.2016.11.001
23.
DevineMF, HerrinC, WarnackW, et al.Novel use of levodopa in human immunodeficiency virus encephalopathy-mediated parkinsonism in an adult. J Postgrad Med, 2018; 64(1):53–55; doi: 10.4103/jpgm.JPGM_674_16
24.
EpsteinMA, AchongBG, BarrYM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet (London, England), 1964; 1(7335):702–703; doi: 10.1016/s0140-6736(64)91524-7
25.
FinkSEK, GandhiMK, NourseJP, et al.A Comprehensive Analysis of the Cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors. Am J Transplant, 2014; 14(11):2577–2587; doi: 10.1111/ajt.12858
26.
FonsekaP, PathanM, Chitti SV, et al.FunRich enables enrichment analysis of OMICs datasets. J Mol Biol, 2021; 433(11):166747; doi: 10.1016/j.jmb.2020.166747
27.
ForteE, SalinasRE, ChangC, et al.The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. J Virol, 2012; 86(12):6889–6898; doi: 10.1128/JVI.07056-11
28.
GorresKL, DaigleD, MohanramS, et al.Valpromide inhibits lytic cycle reactivation of Epstein-Barr virus. MBio, 2016; 7(2):e00113; doi: 10.1128/mBio.00113-16
29.
GregoryCD, MurrayRJ, EdwardsCF, et al.Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med, 1988; 167(6):1811–1824; doi: 10.1084/jem.167.6.1811
30.
GrotheyA, Van CutsemE, SobreroA, et al.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet (London, England), 2013; 381(9863):303–312; doi: 10.1016/S0140-6736(12)61900-X
31.
zur HausenH, Schulte-HolthausenH, KleinG, et al.EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature, 1970; 228(5276):1056–1058; doi: 10.1038/2281056a0
32.
HossainMB, IslamMK, AdhikaryA, et al.Bioinformatics approach to identify significant biomarkers, drug targets shared between Parkinson's disease and bipolar disorder: A pilot study. Bioinform Biol Insights, 2022; 16:11779322221079232; doi: 10.1177/11779322221079232
33.
HuangH-Y, LinY-C-D, LiJ, et al.MiRTarBase 2020: Updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res, 2020; 48(D1):D148–D154; doi: 10.1093/nar/gkz896
34.
HusseinHAM, AkulaSM. MiRNA-36 Inhibits KSHV, EBV, HSV-2 infection of cells via stifling expression of interferon induced transmembrane protein 1 (IFITM1). Sci Rep, 2017; 7(1):17972; doi: 10.1038/s41598-017-18225-w
35.
ImigJ, MotschN, ZhuJY, et al.MicroRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res, 2011; 39(5):1880–1893; doi: 10.1093/nar/gkq1043
36.
IndariO, ChandramohanadasR, JhaHC. Epstein-Barr virus infection modulates blood-brain barrier cells and its co-infection with plasmodium falciparum induces RBC adhesion. Pathog Dis, 2021; 79(1):ftaa080; doi: 10.1093/femspd/ftaa080
37.
InoueY, OhtsukaY. Long-term safety and efficacy of stiripentol for the treatment of dravet syndrome: A multicenter, Open-Label Study in Japan. Epilepsy Res, 2015; 113:90–97; doi: 10.1016/j.eplepsyres.2015.03.012
38.
JakovljevicA, AndricM, KnezevicA, et al.Human cytomegalovirus and Epstein-Barr virus genotypes in apical periodontitis lesions. J Endod, 2015; 41(11):1847–1851; doi: 10.1016/j.joen.2015.08.027
39.
JiangS, WilloxB, ZhouH, et al.Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A. Proc Natl Acad Sci U S A, 2014; 111(1):421–426; doi: 10.1073/pnas.1321704111
40.
JohnsonDR, LevanG, KleinG, et al.Chromosomes and cell surface markers of marmoset lymphocytes and Epstein-Barr virus-transformed marmoset cell lines. Cancer Genet Cytogenet, 1981; 3(2):101–108; doi: 10.1016/0165-4608(81)90064-9
41.
JuurinenL, TiikkainenM, SaltevoJ, et al.Nateglinide combination therapy with basal insulin and metformin in patients with type 2 diabetes. Diabet Med, 2009; 26(4):409–415; doi: 10.1111/j.1464-5491.2009.02691.x
42.
KangBW, ChoiY, KwonOK, et al.High level of viral microRNA-BART20-5p expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. Oncotarget, 2017; 8(9):14988–14994; doi: 10.18632/oncotarget.14744
KimD, KoH-S, Park GBin, et al.Vandetanib and ADAM inhibitors synergistically attenuate the pathological migration of EBV-infected retinal pigment epithelial cells by regulating the VEGF-mediated MAPK pathway. Exp Ther Med, 2017; 13(4):1415–1425; doi: 10.3892/etm.2017.4110
45.
KimH, ChoiH, LeeSK. Epstein-Barr virus MiR-BART20-5p regulates cell proliferation and apoptosis by targeting BAD. Cancer Lett, 2015; 356(2 Pt B):733–742; doi: 10.1016/j.canlet.2014.10.023
46.
KimSY, JeongH-H, KimJ, et al.Robust pathway-based multi-omics data integration using directed random walks for survival prediction in multiple cancer studies. Biol Direct, 2019; 14(1):8; doi: 10.1186/s13062-019-0239-8
47.
KumarS, EspinosaEC, LeandroAC, et al. MicroRNA and MRNA interactions in induced pluripotent stem cell reprogramming of lymphoblastoid cell lines. Am J Stem Cells, 2019; 8(2):28–37.
48.
KurokawaM, AndelaV, GhoshS, et al.Zidovudine: A targeted therapy for endemic Burkitt's lymphoma. East Afr Med J, 2005; 82(9 Suppl):S150-4; doi: 10.4314/eamj.v82i9.9387
49.
LangmeadB, SalzbergSL. Fast Gapped-Read Alignment with Bowtie 2. Nat Methods, 2012; 9(4):357–359; doi: 10.1038/nmeth.1923
50.
LiH, HandsakerB, WysokerA, et al.The sequence alignment/map format and SAMtools. Bioinformatics, 2009; 25(16):2078–2079; doi: 10.1093/bioinformatics/btp352
51.
LiJ, ZhangY, SunL, et al.LMP1 induces P53 protein expression via the H19/MiR-675-5p axis. Microbiol Spectr, 2022; 10(3):e0000622; doi: 10.1128/spectrum.00006-22
52.
LinC, LinK, ZhangB, et al.Plasma Epstein-Barr virus MicroRNA BART8-3p as a diagnostic and prognostic biomarker in nasopharyngeal carcinoma. Oncologist, 2022; 27(4):e340–e349; doi: 10.1093/oncolo/oyac024
53.
LiuA, NakatsukaS-I, YangW-I, et al. Expression of cell adhesion molecules and chemokine receptors: Angioinvasiveness in nasal NK/T-cell lymphoma. Oncol Rep, 2005; 13(4):613–620.
54.
LoveMI, HuberW, AndersS. Moderated estimation of fold change and dispersion for RNA-Seq Data with DESeq2. Genome Biol, 2014; 15(12):550; doi: 10.1186/s13059-014-0550-8
55.
LuoH, LinY, LiuT, et al.DEG 15, an update of the database of essential genes that includes built-in analysis tools. Nucleic Acids Res, 2021a;49(D1):D677–D686; doi: 10.1093/nar/gkaa917
56.
LuoW-J, HeS-W, ZouW-Q, et al.Epstein-Barr virus MicroRNA BART10-3p promotes dedifferentiation and proliferation of nasopharyngeal carcinoma by targeting ALK7. Exp Biol Med (Maywood), 2021b;246(24):2618–2629; doi: 10.1177/15353702211037261
57.
LutherSA, BidgolA, HargreavesDC, et al.Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol, 2002; 169(1):424–433; doi: 10.4049/jimmunol.169.1.424
58.
MaggioEM, Van Den BergA, VisserL, et al.Common and differential chemokine expression patterns in Rs cells of NLP, EBV positive and negative classical hodgkin lymphomas. Int J Cancer, 2002; 99(5):665–672; doi: 10.1002/ijc.10399
59.
MarquitzAR, MathurA, ChughPE, et al.Expression profile of MicroRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells. J Virol, 2014; 88(2):1389–1393; doi: 10.1128/JVI.02662-13
60.
MartinezNJ, WalhoutAJM. The interplay between transcription factors and microRNAs in genome-scale regulatory networks. Bioessays, 2009; 31(4):435–445; doi: 10.1002/bies.200800212
61.
McCarthyDJ, CampbellKR, LunATL, et al.Scater: Pre-processing, quality control, normalization and visualization of single-cell RNA-Seq data in R. Bioinformatics, 2017; 33(8):1179–1186; doi: 10.1093/bioinformatics/btw777
62.
MelisM, VascellariS, SantoruML, et al.Gut microbiota and metabolome distinctive features in Parkinson Disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel. Eur J Neurol, 2021; 28(4):1198–1209; doi: 10.1111/ene.14644
63.
MoX, WeiF, TongY, et al.Lactic acid downregulates viral microRNA to promote Epstein-Barr virus-immortalized B lymphoblastic cell adhesion and growth. J Virol, 2018; 92(9):e00033-18; doi: 10.1128/JVI.00033-18
64.
MusianiM, ZerbiniML, MuscariA, et al. Antibody patterns against cytomegalovirus and Epstein-Barr virus in human atherosclerosis. Microbiologica, 1990; 13(1):35–41.
65.
NaushadSM, HussainT, AlrokayanSA, et al.Development of pharmacogenomic algorithm to optimize nateglinide dose for the treatment of type 2 diabetes mellitus. Pharmacol Rep, 2022; 74(5):1083–1091; doi: 10.1007/s43440-022-00400-0
66.
NiuF, KazimierskaM, NolteIM, et al.The MiR-26b-5p/KPNA2 axis is an important regulator of Burkitt lymphoma cell growth. Cancers (Basel), 2020; 12(6):1464; doi: 10.3390/cancers12061464
67.
OduorCI, MovassaghM, KaymazY, et al.Human and Epstein-Barr virus MiRNA profiling as predictive biomarkers for endemic Burkitt lymphoma. Front Microbiol, 2017; 8:501; doi: 10.3389/fmicb.2017.00501
68.
OkunoY, MurataT, SatoY, et al.Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol, 2019; 4(3):404–413; doi: 10.1038/s41564-018-0334-0
69.
OnnisA, NavariM, AntonicelliG, et al.Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA Hsa-MiR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New Insights into the Pathogenesis of Burkitt Lymphoma. Blood Cancer J, 2012; 2(8):e84; doi: 10.1038/bcj.2012.29
70.
OussaiefL, FendriA, Chane-Woon-MingB, et al.Modulation of MicroRNA cluster MiR-183-96-182 expression by Epstein-Barr virus latent membrane protein 1. J Virol, 2015; 89(23):12178–12188; doi: 10.1128/JVI.01757-15
71.
OyamaT, YamamotoK, AsanoN, et al.Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: A study of 96 patients. Clin Cancer Res, 2007; 13(17):5124–5132; doi: 10.1158/1078-0432.CCR-06-2823
PfefferS, ZavolanM, GrässerFA, et al.Identification of virus-encoded MicroRNAs. Science, 2004; 304(5671):734–736; doi: 10.1126/science.1096781
74.
PullL, LupoglazoffJ-M, BeardmoreM, et al.Artenimol-piperaquine in children with uncomplicated imported falciparum malaria: Experience from a prospective cohort. Malar J, 2019; 18(1):419; doi: 10.1186/s12936-019-3047-9
75.
QiuF, YangL, ZhangL, et al.Polymorphism in mature MicroRNA-608 sequence is associated with an increased risk of nasopharyngeal carcinoma. Gene, 2015; 565(2):180–186; doi: 10.1016/j.gene.2015.04.008
76.
QiuJ, CosmopoulosK, PegtelM, et al.A novel persistence associated EBV MiRNA expression profile is disrupted in neoplasia. PLoS Pathog, 2011; 7(8):e1002193; doi: 10.1371/journal.ppat.1002193
77.
RamayantiO, VerkuijlenSAWM, NoviantiP, et al.Vesicle-bound EBV-BART13-3p MiRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections. Int J Cancer, 2019; 144(10):2555–2566; doi: 10.1002/ijc.31967
78.
SairenjiT, NguyenQV, WodaB, et al. Immune response to intermediate filament-associated, Epstein-Barr virus-induced early antigen. J Immunol, 1987; 138(8):2645–2652.
79.
SakamotoK, SekizukaT, UeharaT, et al.Next-generation sequencing of MiRNAs in clinical samples of Epstein-Barr virus-associated B-cell lymphomas. Cancer Med, 2017; 6(3):605–618; doi: 10.1002/cam4.1006
80.
SalamonD, AdoriM, UjvariD, et al.Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells. J Virol, 2012; 86(8):4701–4707; doi: 10.1128/JVI.06829-11
81.
SamadAFA, SajadM, NazaruddinN, et al.MicroRNA and transcription factor: Key players in plant regulatory network. Front Plant Sci, 2017; 8:565; doi: 10.3389/fpls.2017.00565
82.
ShannonP, MarkielA, OzierO, et al.Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 2003; 13(11):2498–2504; doi: 10.1101/gr.1239303
83.
ShiQ, ZhangY, LiuW, et al.Latent membrane protein 2A inhibits expression level of Smad2 through regulating MiR-155-5p in EBV-associated gastric cancer cell lines. J Med Virol, 2020a;92(1):96–106; doi: 10.1002/jmv.25579
84.
ShiZ, WangR, HuangL, et al.Integrative analysis of MiRNAs-MRNAs reveals that MiR-182 up-regulation contributes to proliferation and invasion of nasopharyngeal carcinoma by targeting PTEN. Aging (Albany NY), 2020b;12(12):11568–11578; doi: 10.18632/aging.103316
85.
ShireK, MarconE, GreenblattJ, et al.Characterization of a cancer-associated Epstein-Barr virus EBNA1 variant reveals a novel interaction with PLOD1 and PLOD3. Virology, 2021; 562:103–109; doi: 10.1016/j.virol.2021.07.009
86.
SunK, JiaK, LvH, et al.EBV-positive gastric cancer: Current knowledge and future perspectives. Front Oncol, 2020; 10:583463; doi: 10.3389/fonc.2020.583463
87.
SzklarczykD, GableAL, LyonD, et al.STRING V11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res, 2019; 47(D1):D607–D613; doi: 10.1093/nar/gky1131
88.
TangN, HuangJ, ChenC, et al.Polymorphisms and haplotypes of IL2RA, IL10, IFNG, IRF5, and CCR2 are associated with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children. Pediatr Blood Cancer, 2021; 68(8):e29097; doi: 10.1002/pbc.29097
89.
TeJL, DozmorovIM, GuthridgeJM, et al.Identification of unique microRNA signature associated with lupus nephritis. PLoS One, 2010; 5(5):e10344; doi: 10.1371/journal.pone.0010344
90.
TsaiP-F, LinS-J, WengP-L, et al.Interplay between PKCδ and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation. J Virol, 2011; 85(5):2373–2385; doi: 10.1128/JVI.01602-10
91.
TsaoSW, TsangCM, LoKW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc London B Biol Sci, 2017; 372(1732):20160270; doi: 10.1098/rstb.2016.0270
92.
TsutsumiN, QuQ, MavriM, et al. Structural basis for the constitutive activity and immunomodulatory properties of the Epstein-Barr virus-encoded G protein-coupled receptor BILF1. Immunity, 2021; 54(7):1405-1416.e7; doi: 10.1016/j.immuni.2021.06.001
UngerleiderN, BullardW, KaraM, et al.EBV MiRNAs are potent effectors of tumor cell transcriptome remodeling in promoting immune escape. PLoS Pathog, 2021; 17(5):e1009217; doi: 10.1371/journal.ppat.1009217
95.
VazirabadiG, GeigerTR, Coffin IiiWF, et al.Epstein-Barr virus latent membrane protein-1 (LMP-1) and Lytic LMP-1 localization in plasma membrane-derived extracellular vesicles and intracellular virions. J Gen Virol, 2003; 84(Pt 8):1997–2008; doi: 10.1099/vir.0.19156-0
96.
WangC, ChevalierD, SalujaJ, et al.Regorafenib and nivolumab or pembrolizumab combination and circulating tumor DNA response assessment in refractory microsatellite stable colorectal cancer. Oncologist, 2020a;25(8):e1188–e1194; doi: 10.1634/theoncologist.2020-0161
97.
WangL, LaingJ, YanB, et al.Epstein-Barr virus episome physically interacts with active regions of the host genome in lymphoblastoid cells. J Virol, 2020c;94(24):e01390-20; doi: 10.1128/JVI.01390-20
98.
WardanaT, GunawanL, HerawatiC, et al.Circulation EBV Mir-Bart-7 relating to clinical manifestation in nasopharyngeal carcinoma. Asian Pac J Cancer Prev, 2020; 21(9):2777–2782; doi: 10.31557/APJCP.2020.21.9.2777
99.
WishartDS, KnoxC, GuoAC, et al.DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res, 2008; 36(Database issue):D901-6; doi: 10.1093/nar/gkm958
100.
WongW-C, NgH-K, TantosoE, et al.Finite-size effects in transcript sequencing count distribution: Its power-law correction necessarily precedes downstream normalization and comparative analysis. Biol Direct, 2018; 13(1):2; doi: 10.1186/s13062-018-0204-y
101.
WroblewskiJM, CoppleA, BatsonLP, et al.Cell Surface phenotyping and cytokine production of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs). J Immunol Methods, 2002; 264(1–2):19–28; doi: 10.1016/s0022-1759(01)00565-8
102.
WuC-C, ChenM-S, ChengY-J, et al.Emodin inhibits EBV reactivation and represses NPC tumorigenesis. Cancers (Basel), 2019; 11(11):1795; doi: 10.3390/cancers11111795
103.
XingB, ShiL, BaoZ, et al.Molecular clustering based on gene set expression and its relationship with prognosis in patients with lung adenocarcinoma. J Thorac Dis, 2022; 14(5):1638–1650; doi: 10.21037/jtd-22-557
104.
XuK, ZhangP, ZhangJ, et al.Identification of potential micro-messenger RNAs (MiRNA-MRNA) interaction network of osteosarcoma. Bioengineered, 2021; 12(1):3275–3293; doi: 10.1080/21655979.2021.1947065
105.
YeJ, GradovilleL, MillerG. Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus Bzlf1 and Brlf1 following cross-linking of the B cell antigen receptor in the Akata Burkitt lymphoma cell line. J Virol, 2010; 84(23):12405–12418; doi: 10.1128/JVI.01415-10
106.
YoungLS, YapLF, MurrayPG. Epstein-Barr Virus: More than 50 years old and still providing surprises. Nat Rev Cancer, 2016; 16(12):789–802; doi: 10.1038/nrc.2016.92
107.
YuG, WangL-G, HanY, et al.ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS, 2012; 16(5):284–287; doi: 10.1089/omi.2011.0118
108.
ZhangR, OuH-Y, ZhangC-T. DEG: A database of essential genes. Nucleic Acids Res, 2004; 32(Database issue):D271-2; doi: 10.1093/nar/gkh024
109.
ZhangX, YanZ, ZhangJ, et al.Combination of Hsa-MiR-375 and Hsa-MiR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol, 2011; 22(10):2257–2266; doi: 10.1093/annonc/mdq758
110.
ZhangY-M, YuY, ZhaoH-P. EBV‑BART‑6‑3p and cellular MicroRNA‑197 compromise the immune defense of host cells in EBV‑positive Burkitt lymphoma. Mol Med Rep, 2017; 15(4):1877–1883; doi: 10.3892/mmr.2017.6173
111.
ZhangY, FanJ, FanY, et al.The New 6q27 Tumor suppressor DACT2, frequently silenced by CpG methylation, sensitizes nasopharyngeal cancer cells to paclitaxel and 5-FU Toxicity via β-Catenin/Cdc25c signaling and G2/M Arrest. Clin Epigenetics, 2018; 10(1):26; doi: 10.1186/s13148-018-0459-2
112.
ZhouL, BuY, LiangY, et al.Epstein-barr virus (EBV)-BamHI-A rightward transcript (BART)-6 and cellular MicroRNA-142 synergistically compromise immune defense of host cells in EBV-Positive Burkitt lymphoma. Med Sci Monit Int Med J Exp Clin Res, 2016; 22:4114–4120; doi: 10.12659/msm.897306
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
